Cardiovascular-Kidney Effects of Dapagliflozin in Patients at Cardiovascular Risk With or Without Type 2 Diabetes: Results of a Randomized, Double-Blind, Placebo-Controlled Trial
Vikas S. Sridhar(University Health Network), David Z.I. Cherney(University Health Network), Josephine Tse(University Health Network), Daan J. Touw(University Medical Center Groningen), Massimo Nardone(University Health Network), Brian Lam(University of Cambridge), Dylan Burger(University of Ottawa), Leif E. Lovblom(University of Toronto), Hiddo J.L. Heerspink(University Medical Center Groningen), Hongyan Liu(University of Toronto), Tomoyuki Tobushi(Mount Sinai Hospital), Yangqing Deng(University Health Network), Yuliya Lytvyn(University Health Network), Luxcia Kugathasan(University of Toronto), Julie A. Lovshin(Sunnybrook Health Science Centre), Jasper Stevens(University Medical Center Groningen), Bruce A. Perkins(Sinai Health System), John S. Floras(Sinai Health System), Tosin Osuntokun(University Health Network)
Cited by 1
Related Papers
Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines
|Journal of Extracellular Vesicles|2018|11.4k
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
|New England Journal of Medicine|2019|6k
Dapagliflozin in Patients with Chronic Kidney Disease
|New England Journal of Medicine|2020|5.2k